BIOPHARMAWIRE  |  RESOURCE LIBRARY  |  INVESTOR KITS

Biotech Valuation Benchmarks 2025-26

Pre-money valuations, round sizes, probability of success rates, and acquisition premiums by stage and therapeutic area — metrics to assess and contextualise company value

Updated Q4 2025  |  BioPharmaWire Editors  |  Sources: Pitchbook, EvaluatePharma, BioCentury, company disclosures, public deal data

Biotech valuation is part science, part narrative, and part market sentiment. The same Phase 1 oncology asset can be valued at $80M in a risk-off market and $300M in a risk-on environment with the same data — because biotech valuations reflect not just the asset but the investor’s appetite for risk and the competitive dynamics among buyers. This guide provides benchmark ranges for pre-money valuations, round sizes, acquisition premiums, and probability of success (PoS) rates by clinical stage and therapeutic area, based on public deal data and market transactions through Q4 2025.

All figures are ranges, not formulas. Use them to contextualise specific situations, not to mechanically derive a number. The most important variables in any specific valuation — team quality, IP defensibility, data quality, competitive landscape, and timing relative to market sentiment — are not captured in a benchmark table.

Private Market Valuation Benchmarks by Stage and Therapeutic Area

Note:  Pre-money valuations reflect the median-to-upper-quartile range for well-positioned companies with strong teams and differentiated science. Distressed situations, weak teams, or crowded therapeutic areas will fall below the low end. Exceptional assets in hot therapeutic areas (obesity, CRISPR, RLT in late 2024-25) have traded above the high end.

Stage	Therapeutic Area	Pre-Money Low	Pre-Money High	Typical Round	Primary Valuation Driver
PRE-SEED / ANGEL (PLATFORM OR PRECLINICAL LEAD)
Pre-Seed	Oncology	$5M	$20M	$1-5M	Founding team pedigree, MOA novelty, IP filing status
Pre-Seed	Rare Disease	$5M	$25M	$1-5M	Orphan designation eligibility, unmet need severity, gene therapy platform
Pre-Seed	Neuroscience	$3M	$15M	$1-4M	Target validation quality, CNS delivery strategy, team neuropsychiatry experience
Pre-Seed	Immunology / Inflammation	$5M	$20M	$1-5M	Novel mechanism vs IL pathway crowding, IP strength, SAB quality
Pre-Seed	Metabolic / Cardiometabolic	$4M	$18M	$1-4M	GLP-1 differentiation thesis, biomarker strategy, CMC feasibility
SEED (IND-ENABLING / PRE-IND)
Seed	Oncology	$15M	$60M	$5-20M	In vivo POC quality, biomarker-selected patient population, first-in-class mechanism
Seed	Rare Disease	$20M	$80M	$5-25M	Natural history data, gene therapy platform specificity, ODD obtained
Seed	Neuroscience	$10M	$45M	$5-15M	CNS target validation, translational biomarkers, clinical-stage comparables
Seed	Immunology / Inflammation	$15M	$55M	$5-20M	Mechanism differentiation vs dupilumab/biologics class, clinical biomarker
Seed	Cell & Gene Therapy	$25M	$100M	$10-35M	Modality (CRISPR premium), manufacturing scalability, ex vivo vs in vivo
Seed	Metabolic / Obesity	$20M	$75M	$8-25M	GLP-1 adjacency, oral vs injectable, weight loss magnitude in animal data
SERIES A (IND FILED / PHASE 1 INITIATED)
Series A	Oncology	$50M	$200M	$20-60M	Phase 1 safety data quality, biomarker-selected ORR signal, KOL buy-in
Series A	Rare Disease	$60M	$250M	$25-75M	Natural history, gene therapy durability data, ODD + BTD obtained
Series A	Neuroscience	$40M	$150M	$20-50M	CNS biomarker (imaging, CSF), Phase 1 tolerability, validated mechanism
Series A	Immunology / Inflammation	$50M	$180M	$20-60M	Head-to-head vs standard of care potential, patient selection precision
Series A	Cell & Gene Therapy	$80M	$350M	$30-100M	Phase 1 durability data, manufacturing scale-up, ex vivo vs in vivo CRISPR
Series A	Metabolic / Obesity	$75M	$300M	$30-90M	Clinical weight loss data vs semaglutide benchmark, safety at dose
Series A	Platform company	$100M	$500M	$40-120M	Number of credible programs, modality defensibility, deal comps for platform
SERIES B (PHASE 1/2 DATA / PHASE 2 INITIATED)
Series B	Oncology	$150M	$600M	$60-150M	Phase 2 ORR vs historical controls, regulatory designation stack, M&A comps
Series B	Rare Disease	$200M	$800M	$75-200M	Phase 2 functional endpoint data, gene therapy durability 12-24 months, reimbursement pathway
Series B	Neuroscience	$120M	$500M	$60-150M	Phase 2 biomarker + functional endpoint concordance, CNS regulatory track record
Series B	Immunology / Inflammation	$150M	$600M	$60-150M	Phase 2 head-to-head or superiority data, label breadth potential
Series B	Metabolic / Obesity	$200M	$900M	$80-200M	Phase 2 weight loss vs semaglutide/tirzepatide, cardiometabolic secondary endpoints
Series B	Platform (multi-program)	$300M	$1.5B	$100-300M	Lead program Phase 2 data + 2nd program Phase 1, platform deal activity
LATE STAGE / PRE-IPO (PHASE 2 PIVOTAL / PHASE 3)
Pre-IPO	Oncology (pivotal)	$400M	$2B+	$100-300M	Phase 3 design quality, FDA interaction, regulatory risk, competitive moat
Pre-IPO	Rare Disease (pivotal)	$500M	$3B+	$150-400M	Single pivotal trial design, ODD + accelerated approval eligibility, manufacturing scale
Pre-IPO	Metabolic (pivotal)	$600M	$4B+	$200-500M	Phase 3 weight loss and cardiovascular outcome data, commercial infrastructure
Pre-IPO	Platform / Multi-asset	$800M	$5B+	$250-600M	Lead asset Phase 3 + pipeline depth, deal activity, IPO market conditions

What Drives Valuation Above or Below the Benchmark

Factors That Drive Valuation Above the Range

Breakthrough Therapy Designation from FDA — typically adds 30-50% to pre-money valuation at Series A vs an undesignated asset at the same stage. BTD signals FDA confidence in the data and unlocks rolling review, which compresses time-to-approval.

First-in-class mechanism in a validated, high-value indication — oncology assets with a novel MOA targeting a well-understood oncogene (KRAS, HER2, EGFR) in an indication with a large biomarker-positive population command significant premiums over best-in-class programs in the same indication.

Platform extensibility — companies that can credibly demonstrate multiple programs from the same platform (modality or biology) trade at a multiple of their lead asset value. The platform premium is real but requires at least one additional program in IND-enabling or Phase 1 to be credible.

Competitive tension — the presence of multiple interested investors or acquirers bidding simultaneously is the single most reliable driver of above-benchmark valuations. Strategic processes run by experienced bankers routinely generate 20-40% premiums over uncontested processes.

Recent deal comps in the therapeutic area — a large acquisition at a high multiple in the same indication in the prior 12 months raises the floor for all subsequent deals in that space. The RayzeBio ($4.1B) and Fusion ($2.4B) RLT acquisitions in late 2024-early 2025 materially repriced the RLT asset market.

Factors That Drive Valuation Below the Range

Single founder / key person risk — companies where one person holds all the scientific knowledge and operational relationships trade at a meaningful discount. Investors price in the cost of replacing that person and the disruption risk.

University IP with onerous terms — license agreements with high royalty rates (above 5%), revenue-sharing on sublicense income, or change-of-control provisions that require licensor consent are red flags that investors discount heavily. The licensor’s ability to derail an acquisition is a hard cap on valuation.

Crowded mechanism — a novel small molecule targeting PD-1 or a CDK4/6 inhibitor for breast cancer will struggle to command a premium valuation regardless of data quality, because the competitive bar is set by marketed products with years of efficacy and safety data. Differentiation must be stark.

CMC / manufacturing weakness — for biologics and cell and gene therapies, an undefined or unscalable manufacturing process is a material discount factor at Series A and beyond. Investors know that manufacturing failures kill programs — they price this risk explicitly.

Acquisition Premiums: Public Company M&A Benchmarks

Note:  Premium percentages represent the premium to the unaffected share price (typically the 30-day VWAP prior to announcement) for publicly listed targets. For private company acquisitions, ‘premium’ is calculated relative to the last funding round valuation, which is a less reliable reference point.

Acquisition Stage	Typical Deal Value	Typical Premium	Therapeutic Area Premium	Key Value Drivers
Phase 1 / Early Phase 2	$200M – $2B	40 – 80%	CGT, RLT, ADC platforms command highest premiums	Novel mechanism, first-in-class, platform extensibility, biomarker-defined population, BTD designation
Phase 2 (data in hand)	$500M – $5B	50 – 100%	Oncology and rare disease attract largest Phase 2 premiums	ORR / PFS superiority vs SoC, regulatory designation stack, acquirer patent cliff urgency, competitive tension from multiple buyers
Phase 3 / Pivotal (pre-data)	$1B – $10B+	30 – 70%	Obesity / GLP-1 adjacency attracting record premiums in 2024-25	Phase 3 design quality, FDA Fast Track / BTD, regulatory risk assessment, CMC readiness, competitive landscape
Phase 3 (positive data)	$3B – $25B+	25 – 60%	Lower premium % but much larger absolute value; competitive bidding raises floor	NDA/BLA readiness, label breadth, commercial infrastructure, payer / reimbursement strategy, patent life remaining
Platform acquisition	$500M – $8B	N/A (pre-revenue)	ADC, RLT, CGT, AI drug discovery platforms most active	Modality defensibility, pipeline depth, manufacturing capability, team retention, acquirer strategic fit

Probability of Success (PoS) Rates: Industry Benchmarks

PoS rates are used in risk-adjusted Net Present Value (rNPV) models — the primary valuation methodology for pre-revenue biotech companies. rNPV multiplies the estimated commercial value of a drug at peak sales by the probability of reaching approval from the current development stage, then discounts for the time value of money. The table below provides industry-average PoS rates by transition, with oncology and non-oncology split.

Note:  PoS rates are historical averages from large-sample industry studies (BIO, Informa, IQVIA). Individual program PoS varies enormously based on mechanism, indication, data quality, and regulatory engagement. Use these as starting points, not conclusions.

Development Phase	Industry PoS (Oncology)	Industry PoS (Other)	Typical Discount Rate	Notes
Preclinical to Phase 1	~65%	~60%	12 – 15%	PoS improves materially with BTD, ODD, or validated biomarker. Biomarker-selected oncology PoS can reach 75-80% pre-to-Phase-1
Phase 1 to Phase 2	~55%	~55%	12 – 15%	Phase 1 safety data is the primary driver. Programs with BTD post-Phase-1 see PoS adjustments upward by 10-20pp in investor models
Phase 2 to Phase 3	~40%	~35%	10 – 12%	The most consequential PoS transition. Phase 2 data quality, endpoint selection, and FDA alignment on Phase 3 design drive major valuation differences here
Phase 3 to NDA/BLA submission	~75%	~70%	8 – 10%	Drops to ~65% for programs with a Complete Response Letter (CRL) risk or contentious safety signals. Accelerated Approval programs require separate PoS for confirmatory trial
NDA/BLA submission to approval	~85%	~80%	8%	CRL rate has been ~15-20% historically. Programs with AdCom risk or manufacturing concerns carry lower PoS at this stage. Advisory committees add ~6 months to timeline if called
Cumulative (Phase 1 to Approval)	~10-15%	~8-12%	Varies	The base rate is sobering. First-in-class oncology with BTD can reach 20-25% cumulative PoS. Rare disease with ODD + BTD + natural history data can reach 30%+

rNPV Methodology: How Biotech Companies Are Valued

The Basic Formula

rNPV = (Peak Year Sales x Operating Margin x Revenue Multiple) x Probability of Approval x Discount Factor for Time to Peak

In practice, most biotech financial models build this up year by year: revenue ramp from approval, COGS and operating costs, terminal value, probability-weighted at each stage transition, and discounted back to present value at the appropriate rate. The key inputs are: peak sales estimate, operating margin (typically 40-60% for a biotech at peak), probability of approval (cumulative PoS from current stage), time to peak sales (typically 5-8 years post-approval), and discount rate.

Peak Sales Estimation

Peak sales are estimated from a patient population model: total diagnosed patients x eligible patients (meeting label criteria) x penetration rate x price x treatment duration. The most important and most frequently wrong assumption is penetration rate. First-in-class drugs in rare disease can achieve 50-80% penetration in 3-5 years. Best-in-class drugs in competitive oncology indications may plateau at 15-25%. Penetration assumptions should be benchmarked against approved drugs in comparable situations.

Discount Rate Selection

The biotech-specific discount rate (typically 10-15%) reflects the risk premium required by investors in a capital-intensive, binary-outcome business. Earlier stage = higher discount rate. Later stage = lower rate as de-risking progresses. For pre-revenue companies, many investors use a 12% discount rate as a baseline and adjust based on asset-specific risk factors: regulatory risk, competitive risk, CMC risk, and market risk.

The Multiple

The enterprise value-to-peak-sales multiple applied in an rNPV model reflects what acquirers historically pay relative to projected peak revenue. In oncology, EV/peak sales multiples for acquisitions have ranged from 2x to 8x depending on indication size, exclusivity period, and competitive landscape. Rare disease assets with high orphan exclusivity have traded at 5-10x. Metabolic disease assets in the GLP-1 adjacency in 2024-25 have traded at 4-8x peak sales.

Biotech-Specific Valuation Considerations for 2026

Several market-specific factors are shaping biotech valuations heading into 2026 that are not fully captured in historical benchmarks:

IRA pricing impact on NDA valuations.  The Inflation Reduction Act’s Medicare drug price negotiation provisions are reducing terminal value assumptions for small molecule drugs with exclusivity periods shorter than 9 years. Biologics (12-year exclusivity) are less affected. Models built before 2022 may significantly overstate NDA asset values for small molecules in large Medicare-eligible populations.

GLP-1 competitive compression.  The commercial success of semaglutide and tirzepatide is compressing the addressable market for several adjacent indications: cardiovascular disease prevention, NASH/MASH, sleep apnoea, and CKD. Assets in these indications need to demonstrate superiority or complementarity to GLP-1 agents — ‘additive to GLP-1’ is now a required frame for many metabolic programs.

AI drug discovery discount.  AI-first drug discovery platforms commanded significant valuation premiums in 2021-2023. As the first wave of AI-designed compounds enter clinical trials, investors are increasingly distinguishing between platforms with clinical-stage assets and those with preclinical-only pipelines. The premium for AI-enabled discovery is narrowing until clinical proof-of-concept is established.

CGT manufacturing premium.  Cell and gene therapy companies with proprietary manufacturing capability — particularly for viral vectors and lentiviral constructs — are trading at a premium to those dependent on third-party CDMOs. In-house manufacturing addresses the capacity constraint that limits commercial scale-up for autologous therapies, and acquirers price this capability into asset valuations.

The benchmarks in this guide are based on publicly available deal data, company disclosures, and industry studies as of Q4 2025. All figures are ranges reflecting observed market transactions and do not constitute a valuation opinion for any specific company or asset. Biotech valuations are highly context-dependent. This document does not constitute financial or investment advice. Founders and investors should engage qualified financial advisors and investment bankers for specific valuation situations.